Log In
BCIQ
Print this Print this
 

VVP100X

  Manage Alerts
Collapse Summary General Information
Company Verva Pharmaceuticals Ltd.
DescriptionNext generation diabetes therapy based on VVP808, a non-thiazolidinedione, non-peroxisome proliferation activated receptor (PPAR)-modulating insulin sensitizer
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentDiscovery
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today